Literature DB >> 11514734

p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3.

Hyun Jin Kwun1, Eun Young Jung1, Ji Young Ahn1, Mi Nam Lee1, Kyung Lib Jang1.   

Abstract

Hepatitis C virus (HCV) NS3 protein is known to affect normal cellular functions, such as cell proliferation and cell death, and to be involved, either directly or indirectly, in HCV hepatocarcinogenesis. In this study, we demonstrated that NS3 protein could specifically repress the promoter activity of p21 in a dose-dependent manner. The effect was not cell type-specific and was synergistic when combined with HCV core protein. Repression of the p21 promoter by NS3 was almost completely lost when p53 binding sites present on the p21 promoter were removed. Furthermore, p53 binding sites were sufficient to confer a strong NS3 responsiveness to an heterologous promoter, suggesting that NS3 represses the transcription of p21 by modulating the activity of p53. Although the NS3 protein domain required for the majority of p21 repression was located on the protease domain, the proteinase activity itself does not seem to be necessary for repression. Both transcription and protein stability of p53 were unaffected by NS3, suggesting that NS3 might repress transcription of p21 by inhibiting the regulatory activity of p53 via protein-protein interaction(s). Finally, the growth rate of NS3-expressing cell lines was at least twice as fast as that of the parent NIH 3T3 cells, indicating that the repression of p21 is actually reflected by the stimulation of cell growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514734     DOI: 10.1099/0022-1317-82-9-2235

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  28 in total

1.  Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 c-terminal deleted protein.

Authors:  Qiong-Qiong He; Rui-Xue Cheng; Yi Sun; De-Yun Feng; Zhu-Chu Chen; Hui Zheng
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways.

Authors:  Enzo Ierardi; Rosa Rosania; Mariangela Zotti; Floriana Giorgio; Simonetta Prencipe; Nicola Della Valle; Vincenzo De Francesco; Carmine Panella
Journal:  World J Gastrointest Oncol       Date:  2010-06-15

Review 3.  AEG-1/MTDH/LYRIC in liver cancer.

Authors:  Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 4.  Cell cycle regulation during viral infection.

Authors:  Sumedha Bagga; Michael J Bouchard
Journal:  Methods Mol Biol       Date:  2014

Review 5.  Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges.

Authors:  Michael J Bouchard; Sonia Navas-Martin
Journal:  Cancer Lett       Date:  2010-12-18       Impact factor: 8.679

Review 6.  Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer.

Authors:  David R McGivern; Stanley M Lemon
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 7.  Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.

Authors:  Elham Shirvani-Dastgerdi; Robert E Schwartz; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2016-08-06       Impact factor: 7.090

8.  Hepatitis C virus core proteins derived from different quasispecies of genotype 1b inhibit the growth of Chang liver cells.

Authors:  Xue-Bing Yan; Lei Mei; Xia Feng; Mei-Rong Wan; Zhi Chen; Nicole Pavio; Christian Brechot
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

9.  Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression.

Authors:  Byoung Kwon Yoo; Luni Emdad; Zao-zhong Su; Augusto Villanueva; Derek Y Chiang; Nitai D Mukhopadhyay; Alan Scott Mills; Samuel Waxman; Robert A Fisher; Josep M Llovet; Paul B Fisher; Devanand Sarkar
Journal:  J Clin Invest       Date:  2009-02-16       Impact factor: 14.808

Review 10.  Prevention of liver cancer.

Authors:  Kathryn Z Guyton; Thomas W Kensler
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.